Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox
Copenhagen University Hospital · Rigshospitalet · +9 more institutions
Abstract
Although body mass index (BMI) is the most commonly used anthropometric measure, newer indices such as the waist-to-height ratio, better reflect the location and amount of ectopic fat, as well as the weight of the skeleton, and may be more useful. METHODS AND RESULTS: The prognostic value of several newer anthropometric indices was compared with that of BMI in patients with heart failure (HF) and reduced ejection fraction (HFrEF) enrolled in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure. The primary outcome was HF hospitalization or cardiovascular death. The association between anthropometric indices and outcomes were comprehensively adjusted for other prognostic variables, including natriuretic peptides. An 'obesity-survival paradox' related to lower mortality risk in those with BMI ≥25 kg/m2 (compared with normal weight) was identified but this was eliminated by adjustment for other prognostic variables. This paradox was less evident for waist-to-height ratio (as an exemplar of indices not incorporating weight) and eliminated by adjustment: the adjusted hazard ratio (aHR) for all-cause mortality, for quintile 5 vs. quintile 1, was 1.10 [95% confidence interval (CI) 0.87-1.39]. However, both BMI and waist-to-height ratio showed that greater adiposity was associated with a higher risk of the primary outcome and HF hospitalization; this was more evident for waist-to-height ratio and persisted after adjustment e.g. the aHR for HF hospitalization for quintile 5 vs. quintile 1 of waist-to-height ratio was 1.39 (95% CI 1.06-1.81).
In patients with HFrEF, alternative anthropometric measurements showed no evidence for an 'obesity-survival paradox'. Newer indices that do not incorporate weight showed that greater adiposity was clearly associated with a higher risk of HF hospitalization.
Citation impact
- FWCI
- 50.31
- Percentile
- 100%
- References
- 62
Authors
12- JHJawad H. Butt
Copenhagen University Hospital, Rigshospitalet, British Heart Foundation, University of Glasgow
- MCMark C. Petrie
British Heart Foundation, University of Glasgow
- PSPardeep S. Jhund
British Heart Foundation, University of Glasgow
- NSNaveed Sattar
British Heart Foundation, University of Glasgow
- ASAkshay S. Desai
Brigham and Women's Hospital
Topics & keywords
- Medicine
- Ejection fraction
- Heart failure
- Anthropometry
- Obesity paradox
- Obesity
- Cardiology
- Heart failure with preserved ejection fraction
- Good health and well-being
Funding
- AAmgen
- ELEli Lilly and Company
- PPfizer
- AAstraZenecaAward: RE/18/6/34217
- GGlaxoSmithKline
- SSanofi
- GSGilead Sciences
- APAlnylam Pharmaceuticals
- BSBoston Scientific Corporation
- CCCelladon Corporation
- RPRegeneron Pharmaceuticals
- IPIronwood Pharmaceuticals, Incorporated
- CCytokinetics
- MMyoKardia
- MModerna
- BHBritish Heart FoundationAwards: 18/6/34217, RE/18/6/34217
- UOUniversity of Glasgow
- DDaiichi-Sankyo
- NNNovo Nordisk
- SServier
- NINational Institutes of Health
- SPSanofi Pasteur
- ARAmerican Regent
- RRespicardia
- RRelypsa
- NHNational Heart, Lung, and Blood Institute
- DSDaiichi Sankyo Europe